Home » Stocks » Matinas BioPharma

Matinas BioPharma Holdings, Inc. (MTNB)

Stock Price: $0.730 USD -0.030 (-3.95%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 145.18M
Revenue (ttm) 89,812
Net Income (ttm) -18.37M
Shares Out 198.87M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 8, 2020
Last Price $0.730
Previous Close $0.760
Change ($) -0.030
Change (%) -3.95%
Day's Open 0.770
Day's Range 0.720 - 0.770
Day's Volume 1,358,657
52-Week Range 0.490 - 2.490

More Stats

Market Cap 145.18M
Enterprise Value 77.97M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 198.87M
Float 159.27M
EPS (basic) -0.13
EPS (diluted) -0.12
FCF / Share -0.08
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 14.04M
Short Ratio 7.20
Short % of Float 7.68%
Beta 2.80
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,616.46
PB Ratio 2.06
Revenue 89,812
Operating Income -21.25M
Net Income -18.37M
Free Cash Flow -16.13M
Net Cash 67.21M
Net Cash / Share 0.34
Gross Margin -12,408.96%
Operating Margin -23,665.26%
Profit Margin n/a
FCF Margin -17,960.30%
ROA -19.64%
ROE -30.46%
ROIC -63.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$3.29*
(350.68% upside)
Low
1.50
Current: 0.730
High
5.00
Target: 3.29
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-------
Operating Income-19.01-14.77-16.65-8.26-10.11-10.46-3.71
Net Income-17.37-14.08-15.49-7.60-9.14-10.22-3.71
Shares Outstanding14598.1090.4857.6551.4832.0819.00
Earnings Per Share-0.13-0.15-0.36-0.21-0.18-0.32-0.20
Operating Cash Flow-14.09-10.32-11.46-6.12-7.81-7.96-2.99
Capital Expenditures-0.41-0.54-0.94--0.08-0.29-0.09
Free Cash Flow-14.50-10.86-12.40-6.12-7.89-8.25-3.08
Cash & Equivalents28.0312.557.464.263.332.6910.84
Total Debt4.230.390.260.140.010.04-
Net Cash / Debt23.8012.167.204.123.322.6510.84
Assets40.2419.9414.429.828.413.3611.33
Liabilities7.193.803.742.672.331.130.86
Book Value33.0516.1410.687.156.072.2310.47
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Matinas BioPharma Holdings, Inc.
Country United States
Employees 21
CEO Jerome D. Jabbour

Stock Information

Ticker Symbol MTNB
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: MTNB

Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.